Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK

BACKGROUND: The cost-effectiveness of umeclidinium bromide-vilanterol (UMEC/VI) versus tiotropium monotherapy in the UK was assessed using a UMEC/VI treatment-specific economic model based on a chronic obstructive pulmonary disease (COPD) disease-progression model. METHODS: The model was implemented...

Descripción completa

Detalles Bibliográficos
Autores principales: Punekar, Yogesh Suresh, Roberts, Graeme, Ismaila, Afisi, O’Leary, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676898/
https://www.ncbi.nlm.nih.gov/pubmed/26692823
http://dx.doi.org/10.1186/s12962-015-0048-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676898/
https://www.ncbi.nlm.nih.gov/pubmed/26692823
http://dx.doi.org/10.1186/s12962-015-0048-6

Ejemplares similares